Text Size

Benefits of switching from latanoprost to preservative-free tafluprost eye drops: A meta-analysis of two phase IIIb clinical trials

Uusitalo H., Egorov E., Kaarniranta K., Astakhov Y., Ropo A.


  • 2016
  • Clinical Ophthalmology
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Clinical development

  • Affiliations

    Department of Ophthalmology, SILK, University of Tampere, Tampere University Hospital, Tampere, Finland; Department of Ophthalmology, The Russian National Research Medical University, Moscow, Russian Federation; Department of Ophthalmology, University of Eastern Finland, Kuopio University Hospital, Kuopio, Finland; Department of Ophthalmology, First Pavlov State Medical University of St Petersburg, Saint Petersburg, Russian Federation; Global Medical Affairs, Santen Oy, Tampere, Finland

Related Publications

Long-term safety and efficacy of sepetaprost, with or without timolol, in patients with open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J2 study

Inatani M., Tone Y., Ikeda T., Angeles R.


Efficacy and safety of sepetaprost in patients with primary open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J1 study

Inatani M., Kanamori A., Inai M., Ikeda T., Angeles R.


Clinical outcomes of Preserflo MicroShunt implant procedure in open‑angle glaucoma patients – a 1000 eyes case-series; including subanalysis of combined cataract-glaucoma surgery and standalone surgery in pseudophakic eyes

Klabe, K.; Werth, J.P.; Kaymak, H. ; Fricke, A.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022